





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification³ : C07C161/04, 101/26 C07F 9/141, 9/65</p>	<p>A1</p>	<p>(11) International Publication Number: WO 84/ 03698 (43) International Publication Date: 27 September 1984 (27.09.84)</p>
<p>(21) International Application Number: PCT/SE84/00089 (22) International Filing Date: 13 March 1984 (13.03.84) (31) Priority Application Number: 8301395-3 (32) Priority Date: 15 March 1983 (15.03.83) (33) Priority Country: SE (71) Applicants (for all designated States except US): LKB-PRODUKTER AB [SE/SE]; Box 305, S-161 26 Bromma (SE). WALLAC, Oy [FI/FI]; Box 10, SF-20101 Turku (FI). (72) Inventors; and (75) Inventors/Applicants (for US only) : MIKOLA, Heikki [FI/FI]; Ruistie 6 B 37, SF-20720 Turku 72 (FI). MUKKALA, Veli-Matti [FI/FI]; Jaakkimank. 7 A 16, SF-20740 Turku 74 (FI). HEMMILÄ, Ilkka [FI/FI]; Paljaspää 6 A 1, SF-20610 Turku 61 (FI). (74) Agent: Johansson, Lars, E.; LKB-Produkter AB, Box 305, S-161 26 Bromma (SE).</p>		<p>(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US. Published With international search report.</p>

(54) Title: COMPOUND



(57) Abstract

Compound having structure (I), where R is a direct chain or branched alkylene group comprising 2-8 carbon atoms; n and m are 0 or 1, Y is a carboxylic or phosphonic acid, and X is an active functional group which permits covalent coupling to a bio-organic molecule.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	KR	Republic of Korea
AU	Australia	LI	Liechtenstein
BE	Belgium	LK	Sri Lanka
BG	Bulgaria	LU	Luxembourg
BR	Brazil	MC	Monaco
CF	Central African Republic	MG	Madagascar
CG	Congo	MR	Mauritania
CH	Switzerland	MW	Malawi
CM	Cameroon	NL	Netherlands
DE	Germany, Federal Republic of	NO	Norway
DK	Denmark	RO	Romania
FI	Finland	SD	Sudan
FR	France	SE	Sweden
GA	Gabon	SN	Senegal
GB	United Kingdom	SU	Soviet Union
HU	Hungary	TD	Chad
JP	Japan	TG	Togo
KP	Democratic People's Republic of Korea	US	United States of America

Compound.

TECHNICAL FIELD

The present invention refers to a compound.

BACKGROUND ART

5 Immunoassay is a field in which the sensitivity of the analysis method often is of decisive importance as the amount of analyte in different biological liquids usually is very low. As a result of this radioisotopes have been widely used as labels in immunoassays despite the disadvantages caused by their use. At the same time, however, a very intense research has been carried out with the aim of replacing the radioisotopes with labels giving at least the same or a higher sensitivity than the isotopes. Fluorescent molecules have in these connections been presented as one of the most potential alternatives to radioisotopes. Comprehensive surveys have recently been published, which give a good general view of fluoroimmunoanalytical determinations known at present (see Smith et al. (1981) Ann. Clin. Biochem. 18, 253-274, Ullman (1981) "Recent Advances in Fluorescence Immunoassay techniques").

The sensitivity of the fluorescent labels in immunoassay, in spite of the fact that it is theoretically very high, has been seriously limited by a high background fluorescence. Usually, it has been possible to reduce the background fluorescence, so that a desired sensitivity could be obtained. The above mentioned surveys also describe the limitations which have made the use of conventional fluorescent labels difficult in immunoassay of analytes which require a high sensitivity corresponding to that which can be obtained with radioisotopes.

The use of time-resolved fluorescence (see Soini et al (1979) Clin. Chem. 25, 353-361) makes it, however, possible to



separate the specific fluorescence of the label from the disturbing, unspecific background fluorescence. The principle of the use of time-resolved fluorescence when following biospecific affinity reactions is described in the U.S. Patent No. 4,374,120 and the European patent application No. 82850077.7. In time-resolved fluorescence the fluorescent label is excited by means of a light pulse of a short duration and the fluorescence is not detected until a certain period of time has elapsed from the excitation pulse. During the time which passes between excitation and detection, the fluorescence from any interfering sources will decay, so that only the signal from the label usable for time-resolved fluorescence is detected. Such a label should have as high fluorescence as possible, a relatively long emission wave-length, a large Stoke's shift and a chemical structure which makes it possible to couple the label covalently to antigens, haptens, antibodies, nucleic acids and polynucleotides. A fluorescence label, which fulfils the above mentioned requirements (U.S. Patent No. 4,374,120) comprises a lanthanide chelate formed by a lanthanide and an aromatic β -diketone, the lanthanide being bound to antigen, hapten, antibody, nucleic acid or polynucleotide via an EDTA-analogue so that a fluorescent lanthanide complex is formed. The fluorescence decay time of the label is long, 50 - 1000 μ sec, which makes it most suitable for the time-resolved detection principle. The fluorescence from the label can either be measured when the marker is bound to antigen, hapten, antibody, nucleic acid or polynucleotide, or the lanthanide can under suitably chosen circumstances be released from these by dissociating the bond between the lanthanide and the EDTA-analogue, the fluorescence being caused in solution in the presence of an aromatic β -diketone, a synergistic compound and a detergent which together with the lanthanide form a micellar system having a fluorescence which is characteristic of the lanthanide (European Patent Application No. 82850077.7).

In the use of lanthanides as labels in biospecific affinity



reactions two functions can in principle be distinguished. On the one hand, the lanthanide should form a fluorescent chelate and on the other hand it should be bound to a bio-organic molecule, which is an antigen, a hapten, an antibody, a nucleic acid or a polynucleotide, in order to be usable as a label in biospecific affinity reactions.

The prerequisites for the formation of a fluorescent lanthanide chelate are described in the European Patent Application No. 83850244.1. A specific controlled binding of a lanthanide to a bio-organic molecule has proved to be difficult even if a number of alternative solutions has been tested. In such a binding it is desirable that the lanthanide is bound to the bio-organic molecule with a very high affinity and that the binding is kinetically stable. The primary ligand which is covalently bound to the bio-organic molecule and which also chelates the lanthanide, can also absorb the excitation energy which is then transferred to the lanthanide according to the principles which are described in the European Patent Application No. 83850244.1, or alternatively the primary ligand only acts as an intermediary for the binding of the lanthanide to the bio-organic molecule. The EDTA analogue mentioned earlier (U.S. Patent No. 4,374,120) follows the latter principle. Aminophenyl-EDTA-Eu can e.g. be diazotated and thereafter be coupled to tyrosine or histidine residues in a protein. The synthesized protein-EDTA-Eu complex gives, however, upon excitation a very low lanthanide fluorescence of a long decay time, since the primary ligand does not absorb and transfer the necessary excitation energy to the lanthanide. In spite of this the ligand functions excellently in biospecific affinity reactions according to the principles which are described in the U.S. Patent No. 4,374,120 and the European Patent Application No. 82850077.7.

Ethylenediamine tetraacetic acid (EDTA) is a well known and commonly used compound, which under suitable conditions forms stable chelates with a large number of metal ions



(see Ringbom (1964) Kompleksometrisk analys). The chelate forming characteristics of the molecule can be utilized to bind e.g. lanthanides to bio-organic molecules for use in bio-specific affinity reactions, if a covalent coupling of the ligand to the bio-organic molecule can be carried out. This has been done by e.g. synthesizing an EDTA dianhydride, which is coupled to a suitable bio-organic molecule, a diaminetriacetic acid derivative of the molecule is, then, obtained when the fourth carboxyl group is used for the conjugation (see Wiedersheim et al, U.S. Patent 4,353,751). Moreover, an aminophenyl-EDTA derivative can be synthesized which can be used to bind the EDTA structure to the bio-organic molecule (see Sundberg et al, U.S. Patent 3,994,966).


There are, however, other compounds than EDTA which form stable chelates with metal ions (see Ringbom (1964) Kompleksometrisk analys). One of them, diethylenetriaminepentaacetic acid (DTPA) has e.g. been used to bind radioisotopes in connection with the examination of kidney functions (see Klopfer et al. (1972) J.Nucl. Med. 13, 107-110). DTPA has also been coupled to protein by the use of a cyclic anhydride of the molecule, four carboxyl groups then remaining for chelating (see: Hnatowich et al. (1982) Int. J. Appl. Radiat. Isot. 33, 327-332).

DISCLOSURE OF INVENTION

- 25 The object of the present invention is to provide a chelating compound, which strongly chelates i.a. lanthanides, but which also comprises active functional groups which makes it possible to bind the metal chelate to a bio-organic molecule comprising e.g. hapten, antigen, nucleic acid or antibody.
- 30 The characteristic features of the invention are apparent from the claims attached to the specification.


BRIEF DESCRIPTION OF DRAWING

The drawing shows a typical AFP determination with duplicate standards for seven different concentrations.



DETAILED DESCRIPTION

Compounds according to the invention can be derived starting from the following basic structure



in which

5 R is a 2 to 8 atoms long covalent bridge comprising alkylene groups

Y comprises carboxylic or phosphonic acid and the number varies depending on n and m.

10 X is an active functional group which permits coupling to a bio-organic molecule and comprises e.g. an aromatic ring comprising a NH_2 , OH, COOH or NCS group:

n and m are 0 or 1.



X can change place with one of the Y functions in the molecule.

15 The chelating compounds can be synthesized in the following ways:

Step 1: 2.0 g diethylenetriamine is dissolved in 25 ml toluene and 1.0 g 4-nitrobenzylbromide dissolved in 25 ml toluene is added. The reaction mixture is stirred for
20 3 hours at room temperature. The precipitate is filtrated and the toluene phase is extracted with water. The water

phase is extracted with chloroform which is evaporated to dryness. The final product consists of a yellow syrup (0.85 g, 77% yield).



TLC: silica gel; ammonia ethanol 1:4; R_f for N^1 compound 0.38 and for N^2 compound 0.29.

$^1\text{H-N.M.R.}$ (CDCl_3): δ = 7.8 (q, 4 H, NO_2 -) , 3.7 for N^2 and 3.9 for N^1 compound (S, 2H, - CH_2 -N), 2.7 (m, 8H, CH_2CH_2 -) 1.6 (S, 2H-NH-&-NH $_2$)

U.V. (H_2O): λ_{max} = 273 nm

- 10 Step 2: The mixture of N^1 - and N^2 - (4-nitrobenzyl)-diethylenetriamine is dissolved in water. The water solution is made alkaline (pH 9-11) with 7 M KOH solution and is heated during stirring to 50°C. A water solution of bromoacetic acid (2.5 g) is added slowly and pH is kept between
- 15 9-11 by means of the KOH solution. After the addition the stirring and the heating (50°C) are continued for at least 4 hours, KOH solution being added now and then to keep pH in between 9 and 11. The reaction mixture is acidified (pH about 1), the insignificant precipitate appearing on the
- 20 cooling, then being filtrated away. The solution is evaporated to a smaller volume, a salt then being precipitated, the precipitation of which is facilitated by adding acetone. The solution is evaporated to dryness and an impure raw product is obtained (3.1 g, containing about 50% of the desired compound). The
- 25 product is purified by means of preparative liquid chromatography (Waters PrepPAK - 500/ C_{18} , with H_2O), then also the different isomers being separated from each other.

TLC: silica gel; acetonitrile/water 4:1; R_f for N^1 compound 0.16 and for N^2 compound 0.33.

30 $^{13}\text{C-N.M.R.}$ (D_2O): δ = 52.4 & 52.6 ($-\text{CH}_2\text{CH}_2-$), 57.8 ($-\text{CH}_2\text{COOH}$) 59.9 (- CH_2 -N), 126.9, 134.3, 141.8 & 150.7 (NO_2 -- CH_2), 173.9 ($-\text{COOH}$) (for N^2 compound)


U.V. (H_2O): λ_{max} \approx 269 nm

I.R. (KBr): ν_{max} = 1740, 1530, 1350 cm^{-1}



Step 3: 2.0 g of a compound from the previous synthesis step is dissolved in 50 ml water and 0.2 g of palladium on activated carbon (5%) is added to the solution in a pressure reactor. The reactor is cooled to 0 - +5°C and is washed with nitrogen gas and hydrogen gas. The reduction takes place at 0 - +5°C at about 1 MPa (pressure above atmospheric). The reaction is followed on thin layer plates (acetonitrile water 4:1), by means of a liquid chromatography (HPLC) or UV-spectrophotometry. Final product 1.7 g, yield 89%.

TLC: silica gel; acetonitrile/water 4:1; R_f for N^1 compound as Eu^{3+} chelate 0.25 and N^2 compound 0.30.

^{13}C -N.M.R. (D_2O): δ = 150.9, 140.9, 121.7 & 120.0 (NO_2 -- CH_2), 183 (-COOH) (for N^2 compound as Eu^{3+} chelate)

U.V. (H_2O) : λ_{max} = 284 & 238 nm ($\sim 1:8$)

I.R. (KBr) : ν_{max} = 1580-1640, 1400 cm^{-1}



Step 4: 2.3 g of N^2 - (4-aminobenzyl)-diethylenetriamine- N^1 , N^1 , N^3 , N^3 - tetraacetic acid is dissolved in about 15 ml of water and the solution is added to a reagent mixture containing 1.7 g of thiophosgene, 15 ml of chloroform and 1 g of sodium hydrogen carbonate. The reaction mixture is strongly stirred for about 20 minutes in room temperature. The phases are separated and the water phase is washed with chloroform (3 x 5 ml), it then being evaporated to dryness and the obtained product is washed with ethanol. Final product 2.2 g, yield 83%.

TLC: Silica gel; acetonitrile/water 4:1; R_f for N^1 and N^2 compounds 0.45

U.V. (H_2O) : λ_{max} = 268 & 280 nm ($\sim 1:1$)

I.R. (KBr): ν_{max} = 2000-2200 cm^{-1}

Reaction scheme:

Step 1:Step 2:

(The isomers are separated by HPLC).

9

Step 3:

Pd/C (5%)

Corresponding aminoderivative

Step 4: $\text{Cl}_2\text{C} = \text{S}$

Corresponding isothiocyanato derivative.

The other compounds mentioned can be synthesized in a corresponding way starting from the corresponding poly-alkylene-polyamine. The carboxylic groups can also be replaced by phosphonic acid (K. MOEDRITZER - R.R. IRANI, J.Org.Chem. 31, 1603 (1966)). The applicability of the invention is illustrated below by means of a non-limiting example of execution.

Example 1. Determination of alphafetoprotein (AFP).

The chelating compound N^2 - (p - isothiocyanato benzyl)-diethylenetriamine - N^1 , N^1 , N^3 , N^3 - tetraacetic acid (p - ITC - B - DTTA) is used to chelate europium and to bind the europium chelate to a monoclonal anti-AFP antibody. The europium labelled antibody was used in the immuno-assay of AFP.

15 Labelling the antibody with europium

p-ITC-B-DTTA-Eu was added to an anti-AFP solution (0.2 mg in 200 μl PBS) at 0°C and the pH of the solution was adjusted to 9.5 by means of 10 μl of 1 M Na_2CO_3 . The molar ratio between chelate and antibody was 60:1. The reaction mixture was incubated over night, whereupon the antibody conjugate was purified from free unreacted label by means of gel filtration on a Sephadex G-50 column (Pharmacia). The degree of conjugation was determined by measuring the europium fluorescence and it was found to be about 7 Eu/IgG.

Immunoassay

Polystyrene tubes were coated with anti-AFP by incubating the tubes over night at room temperature with 250 μ l of a solution containing 1 μ g of anti-AFP in 50 mM K_2HPO_4 +
5 9 g/l of NaCl. The tube surface was saturated with 250 μ l of a solution containing 0.5% of BSA in Tris-HCl buffer, pH 7.70 (2 hours at room temperature). After washing the tubes were used for the immunoassay.

25 μ l serum samples or corresponding standards were incubated
10 for 1 hour in the coated tubes together with 50 ng of europium labelled anti-AFP which had been added in 225 μ l of Tris-HCl buffer, pH 7.7 containing 0.9% NaCl, 0.05% NaN_3 , 0.5% BSA, 0.05% bovine gamma globuline, 0.01% Tween-40 and 20 μ M DTPA. After incubation the tubes were aspirated and
15 washed three times with 2 ml of physiological sodium chloride solution containing 0.05% NaN_3 .

Quantitation of europium by means of time-resolved fluorescence.

The amount of europium, which via the chelate and the labelled antibody has been bound in the immunometric analysis to the
20 surface of the tube, was quantitated by adding 0.5 ml enhancement solution (15 μ M β -naphthoyltrifluoroacetone, 50 μ M trioctylphosphine oxide, 0.1 % of Triton X-100 in phthalate-acetate-buffer pH 3.2). The solution dissociates europium from the chelate, a new fluorescent chelate thus being formed
25 in the micellar phase, the amount of which is proportional to the time-resolved fluorescence signal obtained and the amount of europium released.


Result

The result from a typical AFP determination with duplicate
30 standards for seven different concentrations is shown in Table 1 and on the attached drawing.




Claims

1. Compound having the following structure:



- R is a direct chain or branched alkylene group comprising 2-8 carbon atoms,
 - n and m are 0 or 1,
 - Y is a carboxylic or phosphonic acid, and
 - X is an active functional group which permits covalent coupling to a bio-organic molecule.
2. Compound according to claim 1, wherein the active functional group comprises an alkylene group with 2-8 carbon atoms, a phenyl ring or an aromatic heterocyclic ring which has a NH_2- , $\text{HO}-$, $-\text{COOH}$, isothiocyanate or isocyanate group as a substituent.
3. Compound according to claim 1, wherein X can change place with one of the Y-functions in the molecule.
4. Compound according to claim 1, wherein
- R is an ethylene group,
 - n = m = 0,
 - Y is carboxylic acid, and
 - X is either a p-aminophenyl or a p-isothiocyanatophenyl group.



INTERNATIONAL SEARCH REPORT

International Application No PCT/SE84/00089

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *	
According to International Patent Classification (IPC) or to both National Classification and IPC 3	
C 07 C 161/04, 101/26; C 07 F 9/141, 9/65	
II. FIELDS SEARCHED	
Minimum Documentation Searched *	
Classification System	Classification Symbols
IPC1-3 US C1	C 07 C 161/04, 101/26; C 07 F 9/141, 9/65 <u>260</u> : 112, 454, 482, 518; <u>560</u> : 169
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched *	
SE, NO, DK, FI classes as above	
III. DOCUMENTS CONSIDERED TO BE RELEVANT 14	
Category *	Citation of Document, 15 with indication, where appropriate, of the relevant passages 17
X	DE, A, 2 150 994 (BADISCHE ANILIN- & SODA) FABRIK AG) 19 April 1973 & NL, 7117383 FR, 2118463 GB, 1363099 CA, 956324 AT, 316498 CH, 572461 BE, 776348
X	EP, A1, 0 071 564 (SCHERING AG) 9 February 1983 & DE, 3129906 AU, 86330/82 JP, 58029718
X	DE, A1, 2 918 842 (REXOLIN CHEMICALS AB) 13 December 1979 & FR, 2434141 GB, 1598610 SE, 7904273
X	GB, A, 723 316 (F C BERSWORTH) 9 February 1955 .../...
<p>* Special categories of cited documents: 15</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>	
IV. CERTIFICATION	
Date of the Actual Completion of the International Search *	Date of Mailing of this International Search Report *
1984-06-06	1984-06-25
International Searching Authority *	Signature of Authorized Officer to
Swedish Patent Office	Gerd Wranne
Form PCT/ISA/210 (second sheet) (October 1981)	K.L.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No ¹⁸
X	US, A, 4 374 120 (WALLAC OY) 15 February 1983 & SE, 428332	
X	Patent Abstracts of Japan, abstract of JP 53-23924, published 1978-06-03	
X	DE, A, 2 233 273 (MONSANTO CO) 11 January 1973 & NL, 7209446 FR, 2144853 BE, 785964 GB, 1373858 CA, 1028347	
X	DE, A1, 2 611 813 (MONSANTO CO) 30 September 1976 & US, 3974090 BE, 839798 FR, 2304615 GB, 1504651 CA, 1041115 JP, 51125325	
X	DE, A, 2 015 022 (JOH A BENCKISER GMBH) 28 October 1971 & NL, 7104123 FR, 2085138 BE, 764868	
X	DE, A1, 2 751 943 (CIBA-GEIGY AG) 1 June 1978 & FR, 2372171 US, 4144224 JP, 53068787 GB, 1569669	
X	DE, A1, 2 851 898 (MONTEDISON S.P.A.) 7 June 1979 & BE, 872466 GB, 2010275 NL, 7811637 FR, 2410657 US, 4293466	
X	DE, B2, 2 319 047 (FARBWERKE HOECHST AG) 31 October 1974 & NL, 7404829 FR, 2225439 BE, 813768 US, 3928509 AU, 67837/74 GB, 1441529 AT, 334396 CA, 1012150	
	.../...	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No ¹⁸
	CH, 597252 JP, 50005330	
X	FR, A1, 2 196 992 (CIBA-GEIGY AG) 22 March 1974	
X	DE, A1, 2 357 278 (HOECHST AG) 28 May 1975 & NL, 7414670 BE, 822293 FR, 2251546 US, 3957863 GB, 1484918 CA, 1032176 JP, 50080301	
X	US, A, 3 994 966 (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSI- TY) 30 November 1976	